Gerald R. Ewoldt

Array ( [id] => 16686772 [patent_doc_number] => 20210069247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Compositions for Preparing Regulatory T-Cell Compositions for the Treatment of Autoimmune Disease [patent_app_type] => utility [patent_app_number] => 17/015115 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720113 [patent_doc_number] => 20210087260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => Method of Treating or Preventing Rheumatoid Arthritis [patent_app_type] => utility [patent_app_number] => 16/984515 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16329887 [patent_doc_number] => 20200300853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/897011 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 270 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17220712 [patent_doc_number] => 11173195 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta [patent_app_type] => utility [patent_app_number] => 16/889838 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 32595 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784717 [patent_doc_number] => 11407829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => LAG3 binding peptides [patent_app_type] => utility [patent_app_number] => 16/879884 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8537 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397204 [patent_doc_number] => 20200338062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Inhibitors of the PP1/GADD34 Complex for the Treatment of a Condition Requiring an Immunosuppressive Activity [patent_app_type] => utility [patent_app_number] => 15/931746 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421923 [patent_doc_number] => 20200347121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COLL2-1 PEPTIDE AND ITS NITRATED FORM AS THERAPEUTIC TARGETS FOR OSTEOARTHRITIS TREATMENT [patent_app_type] => utility [patent_app_number] => 16/865703 [patent_app_country] => US [patent_app_date] => 2020-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421938 [patent_doc_number] => 20200347136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => CONSTRAINED CYCLIC PEPTIDES AS INHIBITORS OF THE CD2:CD58 PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF DISEASES AND AUTOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/865295 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215308 [patent_doc_number] => 11590222 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Antibodies that bind human C6 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/864780 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 35815 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18716542 [patent_doc_number] => 11793865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Cultured phagocyte supernatent compositions [patent_app_type] => utility [patent_app_number] => 16/847829 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 12775 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16485363 [patent_doc_number] => 20200378966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => MULTIPLEXED ASSAY KITS FOR EVALUATION OF SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 16/836245 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17394204 [patent_doc_number] => 11243211 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis by assessing genotypes associated with elevated IL-21 [patent_app_type] => utility [patent_app_number] => 16/801009 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 21 [patent_no_of_words] => 15249 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16016089 [patent_doc_number] => 20200182887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Type 1 Diabetes Biomarkers [patent_app_type] => utility [patent_app_number] => 16/791640 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252202 [patent_doc_number] => 20200261576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS [patent_app_type] => utility [patent_app_number] => 16/773982 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190822 [patent_doc_number] => 20200231671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/722296 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16722296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681241 [patent_doc_number] => 20200095284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => MODULATION OF THE IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/676036 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16676036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524755 [patent_doc_number] => 20200054683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => METHODS OF TREATING GRAFT VERSUS HOST DISEASE (GVHD) OR EPIDERMOLYSIS BULLOSA (EB) WITH EXOSOMES [patent_app_type] => utility [patent_app_number] => 16/661657 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18329515 [patent_doc_number] => 11634744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Methods and materials for assessing and treating arthritis [patent_app_type] => utility [patent_app_number] => 16/582042 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 36 [patent_no_of_words] => 7972 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297776 [patent_doc_number] => 20200283499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => Use of an antibody specific for BDCA 2 for ligation and removal of dendritic cells in the treatment systemic lupus erythematosis [patent_app_type] => utility [patent_app_number] => 16/566787 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345277 [patent_doc_number] => 20200010530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => METHODS AND REAGENTS TO TREAT AUTOIMMUNE DISEASES AND ALLERGY [patent_app_type] => utility [patent_app_number] => 16/566716 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566716 [rel_patent_id] =>[rel_patent_doc_number] =>)